← Back to Search

Behavioral Intervention

Virtual Music Therapy for Alzheimer's Disease

N/A

Recruiting

Led By Alexander Pantelyat, MD

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18-89

Mild Cognitive Impairment (MoCA score: 18-25) or Early AD (MoCA score: 17-24)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 1, day 3, day 8, day 10, day 15, day 17, day 22, day 24, day 29, day 31, day 36, day 38, day 43, day 45, day 50, day 52

Awards & highlights

Study Summary

This trial will assess if reminiscence-based virtual music therapy can help people with MCI or mild dementia due to AD by enhancing their autobiographical memory, mood, and cognition.

Who is the study for?

This trial is for adults aged 18-89 with mild cognitive impairment or early Alzheimer's Disease, as indicated by specific scores on a cognitive assessment test (MoCA). It excludes those who've had significant head trauma, are claustrophobic to the extent that they can't undergo MRI scans, have medical devices or metal in their body that interfere with MRI technology.Check my eligibility

What is being tested?

The study tests if virtual music therapy sessions focused on reminiscence can improve memory, mood, and thinking abilities in patients. Participants will attend two sessions per week over eight weeks. Their self-reported feelings and objective measures of cognition will be evaluated before and after treatment using fMRI imaging.See study design

What are the potential side effects?

Since this trial involves non-invasive music therapy, there are no direct physical side effects expected from the intervention itself. However, participants may experience varying emotional responses to the therapy.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 89 years old.

Select...

My memory test score indicates mild cognitive issues or early Alzheimer's.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 1, day 3, day 8, day 10, day 15, day 17, day 22, day 24, day 29, day 31, day 36, day 38, day 43, day 45, day 50, day 52

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 1, day 3, day 8, day 10, day 15, day 17, day 22, day 24, day 29, day 31, day 36, day 38, day 43, day 45, day 50, day 52

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1, day 3, day 8, day 10, day 15, day 17, day 22, day 24, day 29, day 31, day 36, day 38, day 43, day 45, day 50, day 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in autobiographical memory level as assessed by Autobiographical Memory Test (AMT)

Change in scores on neuropsychiatric symptom level as assessed by Neuropsychiatric Inventory Questionnaire (NPI-Q) (caregivers)

Secondary outcome measures

Change in anxiety level as assessed by State-Trait Anxiety Inventory (STAI)

Change in cognition as assessed by the Montreal Cognitive Assessment (MoCA)

Change in cortical activation as assessed by Blood Oxygen Level Dependent (BOLD) on functional magnetic resonance imaging (fMRI)

+4 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Virtual Music TherapyExperimental Treatment1 Intervention

Participants will attend two 30 minutes long virtual music therapy sessions per week for 8 weeks using Zoom.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor

2,260 Previous Clinical Trials

14,820,720 Total Patients Enrolled

Alexander Pantelyat, MDPrincipal InvestigatorDepartment of Neurology, Johns Hopkins School of Medicine

6 Previous Clinical Trials

116 Total Patients Enrolled

Media Library

Virtual Music Therapy (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05151562 — N/A

Alzheimer's Disease Research Study Groups: Virtual Music Therapy

Alzheimer's Disease Clinical Trial 2023: Virtual Music Therapy Highlights & Side Effects. Trial Name: NCT05151562 — N/A

Virtual Music Therapy (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05151562 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What objectives are researchers attempting to accomplish with this research?

"This trial will evaluate the Change in autobiographical memory level as assessed by Autobiographical Memory Test (AMT) over a Baseline and Post-test Week 12 timeframe. Secondary measurements include the percentage of change from baseline blood oxygen levels via Blood Oxygen Level Dependent (BOLD) signal on functional magnetic resonance imaging (fMRI), cognitive abilities through Montreal Cognitive Assessment (MoCA) scores, ranging from 0 to 30 points, and anxiety levels based on State-Trait Anxiety Inventory (STAI)."

Answered by AI

Are individuals currently able to participate in this experimental procedure?

"Per the information hosted on clinicaltrials.gov, it appears that this medical trial is not currently recruiting participants. Despite being first posted on July 18th 2022 and last updated on July 22nd 2022, at present there are no available slots for patients to join in. However, 982 alternate studies appear to be accepting applications presently."

Answered by AI

Does the enrollment criteria for this research accommodate individuals below thirty years of age?

"This research is seeking participants who are elder than the age of consent, yet less than 89 years old."

Answered by AI

Do I meet the criteria necessary to participate in this clinical trial?

"This experiment seeks 60 test subjects that have been diagnosed with Alzheimer's disease, who are aged between 18 and 89. To qualify for this trial, the individual must be within these age limitations and meet either of two cognitive standards - Mild cognitive impairment (MoCA score: 18-25) or Early AD (MoCA score: 17-24)."

Answered by AI